NVST vs. XRAY, BHVN, SMMT, LIVN, PRCT, SHC, RARE, TXG, IDYA, and SGRY
Should you be buying Envista stock or one of its competitors? The main competitors of Envista include DENTSPLY SIRONA (XRAY), Biohaven (BHVN), Summit Therapeutics (SMMT), LivaNova (LIVN), PROCEPT BioRobotics (PRCT), Sotera Health (SHC), Ultragenyx Pharmaceutical (RARE), 10x Genomics (TXG), IDEAYA Biosciences (IDYA), and Surgery Partners (SGRY). These companies are all part of the "medical" sector.
DENTSPLY SIRONA (NASDAQ:XRAY) and Envista (NYSE:NVST) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.
DENTSPLY SIRONA received 428 more outperform votes than Envista when rated by MarketBeat users. Likewise, 61.21% of users gave DENTSPLY SIRONA an outperform vote while only 39.44% of users gave Envista an outperform vote.
DENTSPLY SIRONA has a net margin of -2.41% compared to DENTSPLY SIRONA's net margin of -4.70%. Envista's return on equity of 11.54% beat DENTSPLY SIRONA's return on equity.
DENTSPLY SIRONA currently has a consensus target price of $35.22, indicating a potential upside of 24.55%. Envista has a consensus target price of $25.86, indicating a potential upside of 39.58%. Given DENTSPLY SIRONA's higher probable upside, analysts clearly believe Envista is more favorable than DENTSPLY SIRONA.
In the previous week, Envista had 1 more articles in the media than DENTSPLY SIRONA. MarketBeat recorded 7 mentions for Envista and 6 mentions for DENTSPLY SIRONA. Envista's average media sentiment score of 1.38 beat DENTSPLY SIRONA's score of 1.36 indicating that DENTSPLY SIRONA is being referred to more favorably in the media.
Envista has lower revenue, but higher earnings than DENTSPLY SIRONA. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.
95.7% of DENTSPLY SIRONA shares are owned by institutional investors. 0.5% of DENTSPLY SIRONA shares are owned by company insiders. Comparatively, 1.3% of Envista shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
DENTSPLY SIRONA has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, Envista has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500.
Summary
DENTSPLY SIRONA beats Envista on 12 of the 18 factors compared between the two stocks.
Get Envista News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
